437 related articles for article (PubMed ID: 25973903)
1. Access to orphan drugs in western Europe: can more systematic policymaking really help to avoid different decisions about the same drug?
Kanters TA; Hakkaart L; Rutten-van Mölken MP; Redekop WK
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):557-9. PubMed ID: 25973903
[TBL] [Abstract][Full Text] [Related]
2. What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012).
Wonder M; Chin G
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):843-50. PubMed ID: 25938794
[TBL] [Abstract][Full Text] [Related]
3. Access to orphan drugs in Europe: current and future issues.
Michel M; Toumi M
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
[TBL] [Abstract][Full Text] [Related]
4. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
5. [Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary].
Szegedi M; Molnár MJ; Boncz I; Kosztolányi G
Orv Hetil; 2014 Nov; 155(44):1735-41. PubMed ID: 25344850
[TBL] [Abstract][Full Text] [Related]
6. Economic considerations in the provision of treatments for rare diseases.
McCabe C; Edlin R; Round J
Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
[TBL] [Abstract][Full Text] [Related]
7. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
[TBL] [Abstract][Full Text] [Related]
8. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
9. Pricing and reimbursement of orphan drugs: the need for more transparency.
Simoens S
Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
[TBL] [Abstract][Full Text] [Related]
10. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
Robinson SW; Brantley K; Liow C; Teagarden JR
J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
[TBL] [Abstract][Full Text] [Related]
11. What Does the New Ontario Pharmacare Plan offer Children and Young Adults with Rare Disorders?
Rawson N
J Popul Ther Clin Pharmacol; 2017 Dec; 24(3):90-98. PubMed ID: 29432671
[TBL] [Abstract][Full Text] [Related]
12. How can the risk that orphan drugs present to budgets be managed better?
O'Neill C
Clin Ther; 2010 Aug; 32(9):1640-1. PubMed ID: 20974321
[No Abstract] [Full Text] [Related]
13. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
[TBL] [Abstract][Full Text] [Related]
14. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
[No Abstract] [Full Text] [Related]
15. Issues surrounding orphan disease and orphan drug policies in Europe.
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
[TBL] [Abstract][Full Text] [Related]
16. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
Iskrov G; Miteva-Katrandzhieva T; Stefanov R
Health Policy; 2012 Nov; 108(1):10-8. PubMed ID: 22939047
[TBL] [Abstract][Full Text] [Related]
17. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Zelei T; Molnár MJ; Szegedi M; Kaló Z
Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
[TBL] [Abstract][Full Text] [Related]
18. [Orphan diseases and orphan medicines: a Belgian and European study].
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
[TBL] [Abstract][Full Text] [Related]
19. [European incentives for orphan medicinal products].
Enzmann H; Lütz J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
[TBL] [Abstract][Full Text] [Related]
20. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
Menon D; Clark D; Stafinski T
Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]